The International Metastatic Renal Cell Carcinoma Database Consortium model is predictive of patient survival after targeted therapy for mRCC.
Patients with clear cell RCC and the inherited exonic MET rs11762213 had a worse clinical outcome.
Ipilimumab plus RT vs. RT alone increased median OS in patients with chemotherapy-naïve mCRPC and specific prognostic features.
Trimodal therapy is "appropriate" after transurethral surgery in muscle-invasive bladder urothelial carcinoma not suitable for cystectomy.
Radium-223 dichloride remains an "effective and well-tolerated" treatment for men with CRPC and bone metastases.
LY2157299 monohydrate showed promising efficacy results in patients with advanced HCC tumors overexpressing AFP.
Circulating tumor cells are a useful adjunct in the diagnosis of pancreatic ductal adenocarcinoma.
PET/CT may prevent unnecessary laparotomy by detecting occult metastatic disease in patients with resectable/borderline pancreatic cancer.
Nab-paclitaxel plus gemcitabine sustained overall survival rates compared with gemcitabine alone in patients with metastatic pancreatic adenocarcinoma.
Cetuximab should not be added to first-line FOLFOX4 for patients whose mCRC harbors RAS mutations.
Molecular tumor subtyping offers more accurate prediction of long-term breast cancer outcomes.
Adaptive randomization study finds neoadjuvant veliparib plus carboplatin may improve pCR in TNBC.
Patients with metastatic breast cancer did not benefit from switching to a second-line chemotherapy regimen after one cycle of first-line therapy.
Adding ramucirumab to docetaxel does not improve survival among patients with HER2-negative, advanced breast cancer.
Adding carboplatin or bevacizumab to standard chemotherapy improves pCR in TNBC.
Experts discuss miR-590, a novel STAT5 oncogenic miRNA that targets FasL in AML.
The current system of AE reporting has modest sensitivity and a demonstrable false positive rate in cooperative group trials.
Telomere length may be prognostic of cognitive impairment in women after HCT.
ABT-199 (GDC-0199) demonstrated antitumor activity in patients with high-risk relapsed/refractory CLL and SLL.
Cytogenetic and molecular abnormalities may also be prognostic of post-relapse prognosis.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|